GO
Loading...

Enter multiple symbols separated by commas

Stocks Eli Lilly and Co

More

  • "It's very significant for us," Chief Executive Andrea Pfeifer told Reuters. It had disappointing results in a mid-stage trial last year but Roche has been encouraged by the promise of drugs from Eli Lilly and Biogen that work in a similar way and believes it can do better by raising the dose. AC Immune, backed by SAP co-founder Dietmar Hopp, received an undisclosed...

  • July 23- Eli Lilly and Co's quarterly sales rose for the first time in seven quarters, helped by demand for its new diabetes and cancer drugs as well as the acquisition of Novartis AG's animal health business. Lilly's net profit fell to $600.8 million, or 56 cents per share, from $733.5 million, or 68 cents per share, a year earlier. It also bumped up the lower end of its...

  • July 23- Eli Lilly and Co said its quarterly revenue rose about 1 percent, helped by demand for its new cancer and diabetes treatments and the acquisition of Novartis AG's animal health business. The Indianapolis- based drugmaker's net profit fell to $600.8 million, or 56 cents per share, in the second quarter ended June 30, from $733.5 million, or 68 cents per share, a...

  • Eli Lilly tops Street 2Q forecasts, raises outlook Thursday, 23 Jul 2015 | 6:36 AM ET

    NEW YORK— Eli Lilly and Co. on Thursday reported better-than-expected second-quarter profit on a boost from its recently acquired animal health unit and raised its outlook. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of 74 cents per share. Six analysts surveyed by Zacks expected $4.84 billion in revenue.

  • Brace yourself! Thursday is earnings palooza Wednesday, 22 Jul 2015 | 6:35 PM ET
    Trader on the floor of the New York Stock Exchange.

    Amazon.com, Caterpillar, McDonald's and GM are among the 50 odd companies reporting Thursday, making it the busiest day of the earnings season.

  • Eli Lilly, Biogen shares mixed on Alzheimer's studies Wednesday, 22 Jul 2015 | 12:14 PM ET

    NEW YORK— Shares of Eli Lilly and Co. and Biogen Inc. fell in midday trading following studies on potential Alzheimer's disease treatments that left investors with few answers on the viability of the treatments. On Wednesday, Eli Lilly reported that an experimental medication might slow mild Alzheimer's if people take it early enough. Eli Lilly shares...

  • Biogen, Eli Lilly shares fall on Alzheimer's drug results Wednesday, 22 Jul 2015 | 9:57 AM ET
    Employees at Biogen Idec in Cambridge, MA

    Biogen's Alzheimer's drug showed promise in its latest study, Chief Medical Officer Alfred Sandrock said.

  • WASHINGTON— Eli Lilly& Co. reported Wednesday that an experimental medication might slow mild Alzheimer's if people take it early enough, one of a handful of drugs in late-stage testing in the frustrating hunt for a better treatment. David Knopman of the Mayo Clinic, who has monitored some of Lilly's data. The National Institutes of Health expects to spend $586...

  • Your first trade for Tuesday Monday, 20 Jul 2015 | 6:39 PM ET

    The "Fast Money" traders give their final trades of the day.

  • Alzheimer's drugs on horizon: How do they work? Sunday, 19 Jul 2015 | 1:00 PM ET
    Senior couple with eyes closed

    Medicines in development at Biogen and Eli Lilly could be the first to slow the cognitive declines brought by Alzheimer’s disease. How do they work?

  • A 'Goldilocks' dose for Biogen's Alzheimer's drug? Friday, 17 Jul 2015 | 1:08 PM ET
    A worker in a Biogen lab.

    Biogen is looking to settle on one key thing: the perfect dose for its experimental Alzheimer's drug.

  • DUBLIN, July 16- Britain's Immunocore completed Europe's largest ever financing round by a private life sciences company on Thursday, raising $320 million from investors including Eli Lilly& Co, Malin and Woodford Investment Management. The investment by some of the healthcare sector's "most highly regarded international institutions" is another...

  • July 13- Drug developer Anacor Pharmaceuticals Inc said data showed its experimental ointment to treat an itchy skin condition met the main goal of late-stage studies, sending its shares up more than 50 percent. The condition affects about 9-30 percent of the U.S. population, according to the National Institutes of Health. Other companies developing a...

  • WASHINGTON, July 9- An advisory panel to the U.S. Food and Drug Administration effectively supported approval of Eli Lilly& Co's experimental lung cancer drug necitumumab on Thursday but recommended measures be taken to mitigate the drug's risks. The panel did not officially vote but an informal poll taken by the FDA indicated most members believe the...

  • AstraZeneca divests gastrointestinal drug for $215 mln Thursday, 9 Jul 2015 | 3:07 AM ET

    LONDON, July 9- AstraZeneca struck a further "externalisation" deal on Thursday to help fill its short-term revenue gap by divesting its gastrointestinal drug Entocort for $215 million. The transaction is expected to complete in the second half of 2015 and AstraZeneca said it would reinforce its strategic focus on selected therapy areas, such as cancer,...

  • Your first trade for Thursday, July 9 Wednesday, 8 Jul 2015 | 6:16 PM ET
    Fast Money Final Trade: HD, DXJ, PSG & LLY

    Your first trade for Thursday, July 9

  • Your first trade for Tuesday Monday, 6 Jul 2015 | 6:13 PM ET
    Fast Money Final Trade: LLY, TLT, WTW & BMY

    The "Fast Money" traders give their final trades of the day.

  • LONDON, July 2- Alarmed by rising resistance to antibiotics, the main line of defence against bacterial infections, scientists and governments are taking a fresh look at bacteria-chomping viruses first isolated a century ago from the stools of patients recovering from dysentery. So-called bacteriophages, which attack bacteria but leave human cells...

  • Guess where there is a jobs renaissance in US Friday, 26 Jun 2015 | 10:00 AM ET
    A factory worker assembles transmission components for Chrysler vehicles at the company's Tipton Transmission Plant in Tipton, Indiana.

    Across the nation, manufacturing is still the lifeblood of many US state economies. Here's who tops the list for manufacturing.

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed lower, failing to hold initial gains, as lack of resolution between Greece and its creditors weighed on investor sentiment.